Talazoparib - Pfizer

Drug Profile

Talazoparib - Pfizer

Alternative Names: BMN-673; BMN-673ts; LT 006673; LT-00673; LT-673; MDV-3800; Talazoparib tosylate

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LEAD Therapeutics
  • Developer BioGene Pharmaceutical; BioMarin Pharmaceutical; Center Trials & Treatment; National Cancer Institute (USA); Pfizer; St. Jude Childrens Research Hospital; University of California at San Francisco; University of Maryland Greenbaum Cancer Center; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Fluorobenzenes; Phthalazines; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer; Prostate cancer
  • Phase II Cancer; Ovarian cancer; Small cell lung cancer; Solid tumours
  • Phase I/II Acute myeloid leukaemia
  • Phase I Ewing's sarcoma; Pancreatic cancer
  • Preclinical Glioblastoma; Non-small cell lung cancer
  • Discontinued Haematological malignancies

Most Recent Events

  • 17 Apr 2018 Pfizer plans a phase II trial for Breast Cancer in April 2018 (NCT03499353)
  • 08 Feb 2018 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in Switzerland (PO)
  • 08 Feb 2018 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in Switzerland (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top